I agree 100% with the comment posted on the article. It was very poorly researched. I've taken the liberty of quoting a comment on the article posted on MF
""....However, I suspect Endocyte will need solid results from its NSCLC trial if it has any hope of holding today's big gains..." IS far from the truth....Those results will be years from now and the next catalyst is next weeks CHMP meeting in Europe.... Please research your facts instead of providing incorrect opinions...."
I agree that Motley Fool sucks. Seeking Alpha too. As a point of fact, we are expecting top line data from the phase 2b TARGET trial (NSCLC) in 1Q14. See Endocyte PR dated 10/11/13. Another near term catalyst, hopefully a positive one.
The stool is no different than any of these other clowns they somehow allow a voice. There was a time a number of years back where I kept track of Cramers picks.....most of them. After about 8 months he was 50/50. Nuff said